Labeling index in pituitary adenomas evaluated by means of MIB-1: Is there a prognostic role? A critical review

Neurological Research

Volumn 32, Issue 10, 2010, Pages 1060-1071

  De Aguiar, Paulo Henrique Pires ^a   Aires, Rogério ^b   Laws, Edward R ^c   Isolan, Gustavo Rassier ^d   Logullo, Angela ^e   Patil, Chirag ^f   Katznelson, Laurence ^f  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Santa Casa de Londrina Hospital   (Brazil)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f STANFORD UNIVERSITY   (United States)

Author keywords

Cell growth; Invasion; Ki 67; Labeling index; MIB 1; Pituitary adenomas

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ACTH SECRETING ADENOMA; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL FEATURE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOCYTOCHEMISTRY; INCIDENTALOMA; LABELING INDEX; MITOSIS INDEX; MORPHOLOGY; ONCOCYTOMA; PROGNOSIS; PROLACTINOMA; REVIEW; SEX RATIO; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; HUMANS; KI-67 ANTIGEN; MITOTIC INDEX; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958172287     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12670144737855     Document Type: Review

References (107)

1. Asano K, Kubo O, Tajika Y, Huang MC, Takakura K. The relationship between cell proliferation and secretory activity in pituitary adenomas. A review of 63 cases. No To Shinkei. 1996; 48: 543-49.
2. Atkin SL, Green VL, Hipkin LJ, Landolt AM, Foy PM, Jeffreys RV, et al. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. J Neurosurg. 1997; 87: 85-88.
3. Buchfelder M, Fahlbusch R, Adams EF, Kiesenwetter F, Thiereauf P. Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl (Wien). 1996; 65: 18-21.
4. Daita G, Yonemasu Y. Dural invasion and proliferative potential of pituitary adenomas. Neurol Med Chir (Tokyo). 1996; 36: 211-14.
5. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumor doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien). 1996; 138: 1449-55.
6. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoconal antibody Ki-67. Neurosurgery. 1989; 25: 927-30.
7. Martins AN, Hayes GJ, Kempe LG. Invasive pituitary adenomas. J Neurosurg. 1989; 22: 268-76.
8. Pernicone PJ, Scheithauer BW. Invasive pituitary adenomas and pituitary carcinomas. In: Lloyd RV (ed.). Surgical pathology of the pituitary gland. Philadelphia, PA: WB Saunders; 1993. pp. 121-36.
9. Tsanaclis AM, Robert F, Michaud J, Brem S. The cycling pool of cells within human brain tumors: in situ cytokinetics using the monoclonal antibody Ki-67. Can J Neurol Sci. 1991; 18: 12-17.
10. Hoshino T, Rodriguez LA, Cho KG, Lee KS, Wilson CB, Edwards MS, et al. Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg. 1988; 69: 839-42.
11. Cho KG, Nagashima T, Barnwell S, Hoshino T. Flow cytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms. J Neurosurg. 1988; 69: 588-92.
12. Nagashima T, Murovic JA, Hoshino T, Wilson CB, de Armond SJ. The proliferative potential of human pituitary tumors in situ. J Neurosurg. 1986; 4: 588-93.
13. Aguiar PH, Tatagiba, M, Timpe ED, Matthies C, Samii M, Ostertag H. Proliferative activity of acoustic neurilemomas without neurofibromatosis determined by monoclonal antibody MBI 1. Acta Neurochirur (Wien). 1995; 134: 35-39.
14. Aguiar PH, Tsanaclis AM, Tella Junior OI, Plese JPP. Proliferation rate intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoral oedema and other clinicoradiological and histological characteristics. Neurosurg Rev. 2003; 26: 221-28.
15. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13-20.
16. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkiǹs lymphomas (NHL) as determined in situ with monoclonal antibody Ki-67. Hematol Oncol. 1984; 2: 365-71.
17. Gerdes J, Stein H, Pileri S, Rivano MT, Gobbi M, Ralfkiaer E, et al. Prognostic relevance of tumor-cell growth fraction in malignant non-Hodgkin's lymphomas.Lancet. 1987; 2: 448-49.
18. Gerdes J. Determination of the growth fraction by means of immunostaining with monoclonal antibody Ki-67. Acta Histochem Suppl. 1988; 36: 437-46.
19. Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992; 168: 85-86.
20. Cattoretti G, Becker MH, Key G, Duchrow M, Schwater C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992; 168: 357-363.
21. McCormick D, Chong H, Hobbs C. Detection of the Ki-67antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology. 1993; 22: 355-60.
22. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986; 10: 611-17.
23. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology. 2007; 27: 407-12.
24. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33: 610-17.
25. Tatagiba M, Samii, M, Dankoweit-Timpe E, Aguiar PH, Osterwald L, Babu R, et al. Esthesioneuroblastomas with intracranial extension. Proliferative potential and management. Arq Neuropsiquiatr. 1995; 53: 577-86.
26. Prevedello DM, Jagannathan J, Jane JA, Jr, Lopes MB, Laws ER, Jr. Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg Focus. 2005; 19: E11.
27. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg. 1987; 67: 803-06.
28. Morimura T, Kitz K, Stein H, Budka H. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neurooncol. 1991; 10: 1-11.
29. Hsu DW, Hakim F, Biller BM, de la Monte SM, Zervas NT, Klibanski AH, et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993; 78: 753-61.
30. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996; 38: 99-106.
31. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006; 59: 341-53.
32. Preusser M, Heinzl H, Gelpi E, Schoenegger K, Harberler C, Birner P, et al. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: poor observer agreement limits clinical utility as prognostic factors: a translational research project to the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer. 2006; 107: 162-70.
33. de Lellis RA, Loyd RV, Heitz PU. Pathology and genetics: tumors of the endocrin organs (World Health Organization Classification of tumors). Lyon: International Agency for Research and Cancer; 2004.
34. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg. 2003; 99: 674-79.
35. Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labeling index and tumor size of anterior pituitary adenomas. BMC Cancer. 2001; 1: 12.
36. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunc-tioning pituitary adenomas and carcinomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg. 2003; 98: 359-65.
37. Jaffrain-Rea ML, di Stefano D, Minniti G, Esposito V, Bultrini A, Ferreti E, et al. A critical reapraisal of MIB-1 labelling index significance in a large series of pituitary tumors: secreting versus non secreting adenomas. Endocr Relat Cancer. 2002; 9: 103-13.
38. Yonezawa K, Tamaki N, Kokunai T. Clinical features and growth fractions of pituitary adenomas. Surg Neurol. 1997; 48: 494-500.
39. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, et al. Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci. 2005; 20: 489-94.
40. Abe T, Sanno N, Osamura YR, Matsumoto K. Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochirur (Wien). 1997; 139: 613-18.
41. Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labeling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol. 1999; 52: 107-11.
42. Suzuki M, Minematsu T, Oyama K, Tahara S, Miyai S, Sanno N, et al. Expression of proliferation markers in human pituitary incidentalomas. Endocr Pathol. 2006; 17: 263-75.
43. Delgrande E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997; 82: 2102-07.
44. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, et al. Role of E-cadherin, alpha-, beta-and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol. 2002; 15: 1357-65.
45. Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Boecher-Scwarz HG, Hainfellner J, et al. Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-II alpha. Acta Neurochir (Wien). 2004; 146: 831-39.
46. Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM. Non-functioning pituitary adenoma: immuno-histochemical analysis of 85 cases. Folia Neuropathol. 2007; 45: 72-77.
47. Schaller B. Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study. Pituitary. 2004; 5: 247-53.
48. Scheithauer BW, Kovacs KT, Laws ER, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986; 65: 733-44.
49. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T. Histochemical study of pituitary adenomas with Ki-67 and anti DNA polymerase alpha monoclonal antibodies, bromo-deoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl). 1986; 84: 178-83.
50. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, et al. Proliferation index of nonfunctioning pituitary adenomas: correlation with clinical characteristics and long-term follow up results. Neurosurgery. 2000; 47: 1313-18.
51. Plowman PN. Pituitary adenoma radiotherapy. When, who, and how? Review. Clin Endocrinol. 1999; 51: 265-71.
52. Sheline GE. Pituitary tumors: radiation therapy. In: Beardwell C, Robertson GL (eds.). Clinical endocrinology. The Pituitary. London: Butterworths; 1981. pp. 106-39.
53. Nishioka H, Hirano A, Haraoka J, Nakajima N. Histological changes in the pituitary glands and adenomas following radiotherapy. Neuropathology. 2002; 22: 19-25.
54. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2, expression and angiogenesis in pituitary adenomas: relationship to tumor behavior. Br J Cancer. 2000; 14: 887-900.
55. Henderson WR. The pituitary adenomata. A follow-up study of the surgical results in 338 cases (Dr Harvey Cushing's series). Br J Surg. 1939; 26: 811-921.
56. Jefferson G. The invasive adenomas of the anterior pituitary. 2nd ed. Springfield, IL: Charles C Thomas; 1972. pp. 56-60.
57. Trumble HC. Pituitary tumors. Observations on large tumors which have spread widely beyond the confines of the sella turcica. Br J Surg. 1951; 39: 7-24.
58. Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M. Results of transphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery. 2005; 56: 1222-33.
59. Jefferson G. Extrasellar extension of pituitary adenomas. Proc R Soc Med. 1940; 33: 433-58.
60. Trattnig S, Ba-Ssalamah A, Pinker K, Huhmann I, Wolfsberger S, Knosp E. Imaging of tumors of the pituitary gland. Wien Klin Wochenschr. 2003; 115: 23-27.
61. Losa M, Bazaghi RL, Mortini P, Franzin A, Mangli F, Terreni MR, et al. Determination of the proliferation and apoptotic index in adrenocorticotropin secreting pituitary tumors: comparison between micro-and macroadenomas. Am J Pathol. 2000; 156: 245-51.
62. Iuchi S, Saeki N, Uchino Y, Higuchi Y, Tatsuno I, Nakamura S, et al. Cavernous sinus invasion and tumor proliferative potential of growth hormone producing pituitary tumors. Endocr J. 2000; 47 (Suppl.): S77-79.
63. Iuchi T, Saeki N, Uchino Y, Osato K, Yamaura A. Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth homone secreting pituitary adenomas. Acta Neurochir (Wien). 2000; 142: 1345-51.
64. Saeger W, Lüdecke B, Lüdecke DK. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes. 2008; 116: 80-85.
65. Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol. 2005; 74: 71-76.
66. Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP. Measurement of Ki-67 antigen in 159 pituitary adenomas using MIB-1 monoclonal antibody. Braz J Med Biol Res. 2004; 37: 235-43.
67. Schreiber S, Saeger W, Lüdecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 1999; 1: 213-20.
68. Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher-Schwarz HG, Hainfellner JA, et al. Multiregional sampling reveals a homogeneous distribution of Ki-67 proliferation rate in pituitary adenomas. Acta Neurochir (Wien). 2004; 146: 1323-28.
69. Zhao D, Tomono Y, Nose T. Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien). 1999; 141: 187-92.
70. Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozomi T. MIB-1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien). 1997; 139: 426-31.
71. Lath R, Chacko G, Chandy MJ. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurol India. 2001; 49: 144-47.
72. Nakabayashi H, Sunada I, Hara M. Immunohistochemical analysis of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem. 2001; 49: 1193-94.
73. Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003; 30: 215-19.
74. Ferrante E, Ferraroni M, Castrignano T, Menincatti L, Agnani M, Reimondo G, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol. 2006; 155: 823-29.
75. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumor quiescence and regrowth. Clin Endocrinol (Oxf). 2003; 58: 763-69.
76. Greenman Y, Tordjamn K, Osher E, Veschchev I, Shenkerman G, Reider-Groswasser II, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumor remnant growth. Clin Endocrinol (Oxf). 2005; 63: 39-44.
77. Soto-Ares G, Cortet-Rudelli C, Assaker R, Boulinguez A, Dubest C, Dewailly D, et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur J Endocrinol. 2002; 146: 179-86.
78. Woolons AC, Hun MK, Rajapkase YR, Toomath R, Hamilton DA, Conaglen JV, et al. Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol (Oxf). 2000; 53: 713-17.
79. Fillippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, et al. Pituitary tumor transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf). 2006; 65: 536-43.
80. Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr. 2006; 64: 60-66.
81. Niveiro M, Aranda FI, Paya A, Boix E, Peiro G, Pico A. Oncocytic transformation in pituitary adenomas: Immunohistochemical analyses of 65 cases. Arch Pathol Lab Med. 2004; 128: 776-880.
82. Suliman M, Royds J, Cullen D, Timperly W, Powell T, Battersby R, et al. Mdm2 and P53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf). 2001; 54: 317-25.
83. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007; 14: 887-900.
84. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte T, Hsu DW, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab. 1998; 83: 1619-23.
85. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, et al. Expression of phosphorylated p27 (Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002; 87: 2635-43.
86. Thapar K, Kovacs K, Stefaneau L, Scheithauer B, Killinger DW, Lioyd RV, et al. Overexpression of the growth hormone releasing hormone gene in acromegaly associated pituitary tumors. An event associated with neoplastic progression. Am J Pathol. 1997; 151: 769-84.
87. Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, et al. Relevance of KI-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol. 2007; 157: 141-47.
88. Comtois R, Beauregard H, Somma M, Serri O, Ris-Jilwan N, Hardy J. The clinical and endocrine outcome of transsphe-noidal microsurgery of nonsecreting pituitary adenomas. Cancer. 1991; 68: 860-66.
89. Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macro-adenoma. J Clin Endocrinol Metab. 2006; 91: 1796-801.
90. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab. 2000; 85: 168-74.
91. Honegger J, Ernemann U, Psaras T, Will B. Objective criteria for successful transphenoidal removal of suprasellar nonfunc-tioning pituitary adenomas. A prospective study. Acta Neurochir (Wien). 2007; 149: 21-29.
92. Kurosaki M, Lüdecke DM, Flitsch J, Saeger W. Surgical treatment of clinically nonsecreting pituitary adenomas in elderly patients. Neurosurgery. 2000; 47: 843-48.
93. Lillehei KO, Kirschman DL, Kleinschmidt-Masters BK, Ridgway EC. Reassessment of the role of radiation therapy in the treatment of endocrine inactive pituitary macroadeno-mas. Neurosurgery. 1998; 43: 432-38.
94. Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation-a follow-up study. Clin Endocrinol (Oxf). 1999; 51: 281-84.
95. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Sano T. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007; 61: 580-84.
96. Kim JH, Seo JS, Lee BW, Lee SY, Jeon SH, Lee KB. The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. J Korean Med Sci. 2007; 22 (Suppl.): S61-65.
97. Levy A. Pathogenesis of pituitary adenomas. In: Powell MP, Lightman SL, Laws ER, Jr (eds.). Management of pituitary tumors. The clinician's practical guide. 2nd ed. Chapter 1. Totowa, NJ: Human Press; 2003. pp. 1-20.
98. Romero F, Multon MC, Ramos-Morales, Dominguez A, Bernal JA, Pintor-Toro JA, et al. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001; 29: 1300-07.
99. You R, Ren SG, Horwitz GA, Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol. 2000; 14: 1137-46.
100. Pei L, Melmed S. Isolation and characterization of a pituitary tumor transforming gene (PTTG). Mol Endocrinol. 1997; 11: 433-41.
101. Zhang X, Horowitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999; 84: 761-67.
102. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. P53v expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996; 38: 765-70.
103. Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol. 2001; 52: 195-204.
104. Ferreira JE, de Mello PA, de Magalhães AV, Botelho CH, Naves LA, Nosé V, et al. Non-functioning pituitary adenomas: clinical features and immunohistochemistry. Arq Neuropsiquiatr. 2005; 63: 1070-1078.
105. Liu W, Kunishio K, Matsumoto Y, Okada M, Nagao S. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci. 2005; 12: 791-94.
106. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, et al. Matrix metalloproteinase 9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008; 11: 37-48.
107. Widhalm G, Worfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, et al. Residual nonfunctional pituitary adenomas: prognostic value of MIB labeling index for tumor progression. J Neurosurg. 2009; 111: 563-71.